10

## **CLAIMS**

## What is claimed is:

- 1. An isolated and purified platelet voltage dependent calcium channel (VDCC)  $\alpha_1$  subunit polypeptide.
- 5 2. The isolated and purified platelet VDCC  $\alpha_1$  subunit polypeptide of claim 1, wherein the polypeptide comprises:
  - (a) a polypeptide encoded by a nucleic acid molecule having the nucleotide sequence set forth as any of SEQ ID NOs:1, 3, 5-8, 28, or 29;
  - (b) a polypeptide encoded by a nucleic acid molecule that is substantially identical to any of NOs:1, 3, 5-8, 28, or 29;
  - (c) a polypeptide having the amino acid sequence set forth as SEQ DI NO:2 or 4;
  - (d) a polypeptide that is a biological equivalent of the polypeptide of SEQID NO:2 or 4; or
- (e) a polypeptide which is immunologically cross-reactive with an antibody that shows specific binding with a polypeptide of SEQ ID NO:2 or 4.
- 3. The polypeptide of claim 1, wherein the platelet VDCC  $\alpha_1$  subunit polypeptide comprises a platelet VDCC  $\alpha_1$ S subunit polypeptide or a platelet VDCC 20  $\alpha_1$ D subunit polypeptide.
  - 4. The polypeptide of claim 1, modified to be in detectably labeled form.
  - 5. An isolated and purified antibody capable of specifically binding to a polypeptide of claim 1.
- 6. The antibody of claim 5, wherein the antibody is capable of modulating 25 the biological activity of the polypeptide to which it specifically binds.
  - 7. A hybridoma cell line which produces an antibody of claim 5.
  - 8. An isolated and purified nucleic acid molecule encoding a platelet VDCC  $\alpha_1$  subunit polypeptide of claim 1.
- 9. The nucleic acid molecule of claim 8, wherein the encoded platelet 30 VDCC α<sub>1</sub> subunit polypeptide comprises a platelet VDCC α<sub>1</sub>S subunit polypeptide or a platelet VDCC α<sub>1</sub>D subunit polypeptide.

- 10. The nucleic acid molecule of claim 8, wherein the encoded polypeptide comprises:
  - (a) a polypeptide having the amino acid sequence set forth as SEQ ID NO:2 or 4;
- 5 (b) a polypeptide that is a biological equivalent of the polypeptide of SEQ ID NOs:2 or 4; or
  - (c) a polypeptide which is immunologically cross-reactive with an antibody that shows specific binding with a polypeptide of any of SEQ ID NO:2 or 4.
- 10 11. The nucleic acid molecule of claim 8, comprising:
  - (a) a nucleic acid molecule having the nucleotide sequence set forth as any of SEQ ID NOs:1, 3, 5-8, 28, or 29;
  - (b) a nucleic acid molecule that is substantially identical to any of SEQ ID NOs:1, 3, 5-8, 28, or 29;
- 15 12. The isolated nucleic acid molecule of claim 8, comprising a 20 nucleotide sequence that is identical to a contiguous 20 nucleotide sequence of SEQ ID NOs:28 or 29.
  - 13. The nucleic acid molecule of claim 8, further defined as a DNA segment.
- 20 14. The nucleic acid molecule of claim 13, further defined as positioned under the control of a promoter.
  - 15. The nucleic acid molecule of claim 14, wherein said DNA segment and promoter are operationally inserted into a recombinant vector.
- 16. A recombinant host cell comprising the nucleic acid molecule of claim 25 8.
  - 17. The recombinant host cell of claim 16, wherein the cell further comprises a platelet or a megakaryocyte.
  - 18. A method of producing an antibody that specifically binds a platelet VDCC  $\alpha_1$  subunit polypeptide, the method comprising:
- 30 (a) transfecting a recombinant host cell with a nucleic acid molecule that encodes a platelet VDCC α<sub>1</sub> subunit polypeptide of claim 1;
  - (b) culturing the host cell under conditions sufficient for expression of the polypeptide;

- (c) recovering the polypeptide; and
- (d) preparing an antibody to the polypeptide, wherein the antibody specifically binds the polypeptide.
- 19. The method of claim 18, wherein the polypeptide comprises a 5 polypeptide as set forth as SEQ ID NO:2 or 4.
  - 20. The method of claim 18, wherein the nucleic acid molecule comprises a nucleotide sequence as set forth in any of SEQ ID NOs:1, 3, 5-8, 28, or 29.
- 21. A method of detecting a platelet VDCC α<sub>1</sub> subunit polypeptide, the method comprising immunoreacting the polypeptide with an antibody prepared 10 according the method of claim 18 to form an antibody-polypeptide conjugate; and detecting the conjugate.
  - 22. An assay kit for detecting the presence of a platelet VDCC  $\alpha_1$  subunit polypeptide in a biological sample, the kit comprising a first antibody that specifically binds a polypeptide of claim 1.
- 15 23. The assay kit of claim 22, further comprising a second container containing a second antibody that immunoreacts with the first antibody.
  - 24. The assay kit of claim 23, wherein the first antibody and the second antibody comprise monoclonal antibodies.
- 25. The assay kit of claim 23, wherein the first antibody is affixed to a solid 20 support.
  - 26. The assay kit of claim 23, wherein the first and second antibodies each comprise an indicator.
  - 27. The assay kit of claim 26, wherein the indicator is a radioactive label or an enzyme.
- 28. An assay kit for detecting the presence, in a biological sample, of an antibody that specifically binds a platelet VDCC  $\alpha_1$  subunit polypeptide, the kit comprising a polypeptide of claim 1 that specifically binds the antibody, wherein the polypeptide is present in an amount sufficient to perform at least one assay.
- 29. A method of detecting a nucleic acid molecule that encodes a platelet 30 VDCC  $\alpha_1$  subunit polypeptide in a biological sample containing nucleic acid material, the method comprising:

5

- (a) hybridizing the nucleic acid molecule of claim 8 under stringent hybridization conditions to the nucleic acid material of the biological sample, thereby forming a hybridization duplex; and
- (b) detecting the hybridization duplex, whereby a platelet VDCC  $\alpha_1$  subunit polypeptide is detected.
- 30. A method to determine the presence or absence of a mutation conferring altered VDCC  $\alpha_1$  subunit activity in a platelet, said method comprising the step of analyzing a nucleic acid or protein sample for the presence of a mutation in a nucleic acid molecule encoding the platelet VDCC  $\alpha_1$  subunit polypeptide of claim 10.1.
  - 31. The method of claim 30, further comprising:
  - (a) amplifying nucleic acid molecules in said sample using a nucleic acid amplification method and primers that selectively amplify said nucleic acid molecule encoding a platelet VDCC α₁ subunit polypeptide; and
- 15 (b) identifying whether a mutation is present in said amplified nucleic acid molecule.
  - 32. The method of claim 31, further comprising the step of analyzing a protein sample for the presence of a mutation in a platelet VDCC  $\alpha_1$  subunit polypeptide.
- 20 33. A method for detecting a polymorphism in a nucleic acid molecule that encodes a platelet VDCC α₁ subunit polypeptide, the method comprising:
  - (a) amplifying nucleic acid molecules in said sample using a nucleic acid amplification method and primers that selectively amplify said nucleic acid molecule encoding a platelet VDCC α<sub>1</sub> subunit polypeptide; and
- 25 (b) identifying whether a polymorphism is present in said amplified nucleic acid molecule.
  - 34. A kit for detecting a polymorphism in a nucleic acid molecule encoding a platelet VDCC  $\alpha_1$  subunit polypeptide, the kit comprising:
- (a) a reagent for detecting a polymorphism in a nucleic acid molecule
  30 encoding a platelet VDCC α<sub>1</sub> subunit polypeptide in a biological sample; and
  - (b) a container for the reagent.

15

- 35. The kit of claim 34, further comprising a reagent for amplifying a nucleic acid molecule encoding a platelet VDCC  $\alpha_1$  subunit polypeptide.
- 36. The kit of claim 35, wherein the amplifying reagent comprises a polymerase enzyme suitable for use in a polymerase chain reaction and a pair of 5 oligonucleotides.
  - 37. The kit of claim 35, further comprising a reagent for extracting a nucleic acid sample from a biological sample obtained from a subject.
  - 38. A method of screening candidate substances for an ability to modulate platelet VDCC  $\alpha_1$  subunit biological activity, the method comprising:
- (a) establishing a test sample comprising a nucleic acid molecule encoding a platelet VDCC α₁ subunit polypeptide;
  - (b) administering a candidate substance to the test sample; and
  - (c) measuring the interaction, effect, or combination thereof, of the candidate substance on the test sample to thereby determine the ability of the candidate substance to modulate platelet VDCC  $\alpha_1$  subunit biological activity.
  - 39. The method of claim 38, wherein the candidate substance is a candidate protein, a peptide, an antibody, a nucleic acid, or a chemical compound.
- 40. The method of claim 39, further comprising the step of purifying and 20 isolating a gene encoding the candidate polypeptide.
  - 41. The method of claim 39, wherein the platelet VDCC  $\alpha_1$  subunit polypeptide is contained within cells in cell culture.
    - 42. A recombinant cell line suitable for use in the method of claim 41.
- 43. The method of claim 38, further comprising a modulatable 25 transcriptional regulatory sequence of a platelet VDCC  $\alpha_1$  subunit polypeptide-encoding gene and a reporter gene which is capable of producing a detectable signal, wherein a candidate substance as a modulator of platelet VDCC  $\alpha_1$  subunit biological activity is based on the amount of signal produced in relation to a control sample.
- 30 44. The method of 43, wherein the reporter gene encodes the platelet VDCC  $\alpha_1$  subunit polypeptide of claim 1.
  - 45. A method of modulating platelet VDCC  $\alpha_1$  subunit polypeptide biological activity in a cell, the method comprising administering to the cell an

effective amount of a substance capable of modulating activity of a platelet VDCC  $\alpha_1$  subunit polypeptide in the cell to thereby modulate platelet VDCC  $\alpha_1$  subunit polypeptide biological activity in the cell.

- 46. The method of claim 45, wherein the cell is a platelet or a 5 megakaryocyte.
  - 47. The method of claim 46, wherein the cell comprises a cell in a vertebrate subject.
    - 48. The method of claim 47, wherein the vertebrate subject is a mammal.
- 49. The method of claim 45, wherein the step of administering further 10 comprises administering an effective amount of a substance that modulates expression of a platelet VDCC  $\alpha_1$  subunit polypeptide-encoding nucleic acid molecule in the cell.
- 50. The method of claim 45, wherein the substance that modulates the platelet VDCC α<sub>1</sub> subunit biological activity comprises an anti-platelet VDCC α<sub>1</sub>
  15 subunit polypeptide antibody, a polypeptide, a peptide, a chemical compound, or a nucleic acid.
  - 51. The method of claim 50, wherein the nucleic acid substance that modulates expression of a platelet VDCC  $\alpha_1$  subunit polypeptide-encoding nucleic acid molecule comprises an antisense oligonucleotide.
- 52. The method of claim 50, wherein the polypeptide, peptide, or chemical compound substance that modulates expression of the platelet VDCC  $\alpha_1$  subunit polypeptide-encoding nucleic acid molecule comprises a ligand for a modulatable transcriptional regulatory sequence of a platelet VDCC  $\alpha_1$  subunit polypeptide-encoding nucleic acid molecule.
- 53. A pharmaceutical composition comprising a therapeutically effective amount of a modulator of a biological activity of a platelet VDCC  $\alpha_1$  subunit polypeptide, and combinations thereof, and a pharmaceutically acceptable diluent or vehicle.
- 54. The pharmaceutical composition of claim 53, wherein the platelet 30 VDCC α<sub>1</sub> subunit polypeptide-biological-activity-modulator preferentially binds a platelet VDCC α<sub>1</sub> subunit polypeptide, or a fragment or derivative thereof.
  - 55. A method for modulating calcium transport in a cell, the method comprising introducing to the cell a construct comprising a nucleic acid sequence

encoding a platelet VDCC  $\alpha_1$  subunit polypeptide operatively linked to a promoter, wherein production of the platelet VDCC  $\alpha_1$  subunit polypeptide in the cell results in modulation of calcium transport.

- 56. The method of claim 55, wherein the construct further comprises a 5 vector selected from the group consisting of a plasmid vector or a viral vector.
  - 57. The method of claim 55, wherein the construct further comprises a liposome complex.
  - 58. The method of claim 55, wherein the cell is a platelet or a megakaryocyte.
- 10 59. The method of claim 55, wherein the cell comprises a cell in a vertebrate subject.
  - 60. The method of claim 59, wherein the vertebrate subject is a mammal.
- 61. A transgenic non-human animal having incorporated into its genome a nucleic acid molecule encoding a human platelet VDCC  $\alpha_1$  subunit polypeptide, 15 wherein the human platelet VDCC  $\alpha_1$  subunit polypeptide is expressed in the transgenic non-human animal.
  - 62. A transgenic non-human animal having modified or deleted from its genome a nucleic acid molecule encoding a platelet VDCC  $\alpha_1$  subunit polypeptide.